Ledger.Open graph →
SEC Form D · Amendment · filed July 1, 2016

G1 Therapeutics, Inc

Offering
$50.0M
Sold
$50.0M
Exemption
Rule 506(b)
Industry
Biotechnology
Location
RESEARCH TRIANGLE PARK, NC
Type
—

Rule 506(b): private placement to accredited investors, no public advertising.

People & firms on this filing (26)

Frederic N. Eshelman · RESEARCH TRIANGLE PARK, NCDirectorPeter A. Kolchinsky · RESEARCH TRIANGLE PARK, NCDirectorRon A. Laufer · RESEARCH TRIANGLE PARK, NCDirectorGregory N. Mossinghoff · RESEARCH TRIANGLE PARK, NCExecGlenn A. Muir · RESEARCH TRIANGLE PARK, NCDirectorTimothy N. Sullivan · RESEARCH TRIANGLE PARK, NCDirectorMark A. Velleca · RESEARCH TRIANGLE PARK, NCExec · DirectorSeth A. Rudnick · RESEARCH TRIANGLE PARK, NCDirectorChristy A. Shaffer · RESEARCH TRIANGLE PARK, NCDirectorSteven J. Dietz · Santa Monica, CAExecClive T. Johnson · Vancouver, British Columbia, CanadaDirectorCharles R. Nightingale · Irvine, CADirectorGlenn A. Muir · RESEARCH TRIANGLE PARK, NCDirectorMark Oei · Menlo Park, CADirectorJeanmarie Guenot · San Francisco, CADirectorRoger T. Richer · Vancouver, British Columbia, CanadaDirectorPeter A. Kolchinsky · RESEARCH TRIANGLE PARK, NCDirectorIrwin Gross · Menlo Park, CADirectorKristin S. Lowe · Santa Monica, CADirectorAntony D. Lundy · Greenwich, CTExec · DirectorWilliam S. Lowe · Santa Monica, CAExec · DirectorDouglas K. Johnson · FORT MILL, SCExecBrian Litvack · New York, NYDirectorMatthew Gorin · New York, NYDirectorJeremy Goldberg · New York, NYDirectorParamdeep Singh · New York, NYDirector

Public SEC Form D (Reg D) filing. · View issuer on SEC EDGAR ↗